Welcome to our dedicated page for Infusystem Hld SEC filings (Ticker: INFU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
InfuSystem Holdings, Inc. filings document financial reporting, governance and material-event disclosures for a health care service provider focused on outpatient durable medical equipment services. Recent 8-K filings furnish earnings releases, conference-call announcements, investor presentations and Regulation FD disclosures tied to Patient Services and Device Solutions.
The company’s proxy materials cover board matters, shareholder voting, executive compensation and equity award disclosures. Other filings document accounting oversight, including changes in the independent registered public accounting firm, audits of consolidated financial statements and internal control over financial reporting.
InfuSystem Holdings, Inc. furnished an updated investor presentation dated October 6, 2025, under a Regulation FD disclosure. The presentation is attached as Exhibit 99.1 to this current report. The company states that the information in this section and in the investor presentation is being furnished rather than filed, so it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities law filings.
Insider filing for Carrie Lachance, President and CEO of InfuSystem Holdings (INFU). On 09/23/2025, 50,000 performance-based restricted stock units granted May 16, 2025, vested and were settled into common stock. The issuer withheld 19,675 shares to cover tax withholding at an indicated value of $10.22 per share, leaving the reporting person with 232,174 shares beneficially owned after the transactions. The Form 4 shows the reporting person held 201,849 shares before the vesting, which increased to 251,849 upon settlement then decreased due to withholding. This filing documents routine equity compensation vesting and related tax withholding by an executive who is also a director.
InfuSystem Holdings, Inc. filed a current report to share that its President and Chief Executive Officer, Carrie Lachance, and its Chief Financial Officer, Barry Steele, will participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025. The participation was announced in a press release dated September 25, 2025, which is included as Exhibit 99.1 and furnished under Regulation FD, meaning it is provided for information purposes and is not treated as filed for liability purposes. The report also includes an Inline XBRL cover page data file as Exhibit 104.
InfuSystem Holdings insider Scott Shuda reported changes in beneficial ownership. Mr. Shuda, identified as a director, disclosed indirect ownership of 298,383 shares through entities Meridian and BlueLine. He recorded a distribution on 07/07/2025 that reduced holdings by 2,242 shares and a sale on 08/22/2025 of 5,752 shares at an average price of $9.67 (individual sale prices ranged $9.57–$9.83). Following the reported transactions, the filing shows 94,000 shares owned (direct or indirect) after the August sale. The Form 4 notes the sold shares originated from a dissolved partnership and no further sales are planned relating to that partnership.
InfuSystem Holdings, Inc. (INFU) filed a Form 144 notifying an intended open-market sale of 5,752 common shares through Charles Schwab with an aggregate market value of $56,455. The filing states the shares were originally acquired on 08/01/2017 via open-market purchase and payment in cash. The proposed approximate sale date is 08/22/2025, and the filing reports 20,425,964 shares outstanding for the issuer. No securities of the issuer were reported sold by the same person in the past three months. The filer affirms they are not aware of any undisclosed material adverse information.
AWM Investment Company, Inc. filed an amendment to Schedule 13G reporting beneficial ownership of 1,272,296 shares of InfuSystem Holdings, Inc. common stock, representing 6.1% of the outstanding class. AWM states it is the investment adviser to Special Situations Life Sciences Fund, L.P. (SSLS) and holds sole voting and sole dispositive power over the shares held by SSLS. The filing discloses Delaware organization for AWM, the issuer's principal office in Rochester Hills, Michigan, and confirms the stake was acquired and is held in the ordinary course of business, not for the purpose of changing control.